Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Feb;49(2):471-483.
doi: 10.1007/s00261-023-04143-1. Epub 2024 Jan 10.

Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis

Shuwei Zhou  1 , Siyu Wang  2 , Jian Xiang  3 , Zhongyu Han  4 , Weilang Wang  1 , Shuhang Zhang  1 , Noble Chibuike Opara  1 , Shenghong Ju  1 , Ying Cui  5 , Yuan-Cheng Wang  6
Affiliations
Meta-Analysis

Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis

Shuwei Zhou et al. Abdom Radiol (NY). 2024 Feb.

Abstract

Purpose: The ideal contrast agent for imaging patients with hepatocellular carcinoma (HCC) following locoregional therapies (LRT) remains uncertain. We conducted a meta-analysis to assess the diagnostic performance of magnetic resonance imaging with extracellular contrast agent (ECA-MRI) and hepatobiliary agent (EOB-MRI) in detecting residual or recurrence HCC following LRT.

Methods: Original studies comparing the diagnostic performance of ECA-MRI and EOB-MRI were systematically identified through comprehensive searches in PubMed, EMBASE, Cochrane Library and Web of Science databases. The pooled sensitivity and specificity of ECA-MRI and EOB-MRI were calculated using a bivariate-random-effects model. Subgroup-analyses were conducted to compare the diagnostic performance of ECA-MRI and EOB-MRI according to different variables. Meta-regression analysis was employed to explore potential sources of study heterogeneity.

Results: A total of 15 eligible studies encompassing 803 patients and 1018 lesions were included. Comparative analysis revealed no significant difference between ECA-MRI and EOB-MRI in the overall pooled sensitivity (87% vs. 79%) and specificity (92% vs. 96%) for the detection of residual or recurrent HCC after LRT (P = 0.41), with comparable areas under the HSROC of 0.95 and 0.92. Subgroup analyses indicated no significant diagnostic performance differences between ECA-MRI and EOB-MRI according to study design, type of LRT, most common etiology of liver disease, baseline lesion size, time of post-treated examination and MRI field strength (All P > 0.05).

Conclusion: ECA-MRI exhibited overall comparable diagnostic performance to EOB-MRI in assessing residual or recurrent HCC after LRT.

Keywords: Contrast agent; Diagnostic performance; Hepatocellular carcinoma; Locoregional therapies; Magnetic resonance imaging.

PubMed Disclaimer

References

    1. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2018;67:358-80. https://doi.org/10.1002/hep.29086 - DOI - PubMed
    1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019 - DOI
    1. Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature reviews Gastroenterology & hepatology. 2021;18:293-313. https://doi.org/10.1038/s41575-020-00395-0 - DOI
    1. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-91.e1. https://doi.org/10.1053/j.gastro.2018.08.065 - DOI - PubMed
    1. Youn SY, Kim B, Kim DH, Choi HJ, Sung PS, Choi JI. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma. European radiology. 2022;32:6270-80. https://doi.org/10.1007/s00330-022-08720-8 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources